The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
Geoffrey Shapiro
Research Funding - Cellceutix
Jeffrey G Supko
Research Funding - Cellceutix
Daniel C. Cho
No relevant relationships to disclose
John Frederick Hilton
No relevant relationships to disclose
Matthew Hadfield
No relevant relationships to disclose
Solida Pruitt-Thompson
No relevant relationships to disclose
Eveline Bordoli-Trachsela
No relevant relationships to disclose
Nela Zvereva
No relevant relationships to disclose
Andrew Wolanski
No relevant relationships to disclose
Aya Sato-DiLorenzo
No relevant relationships to disclose
Susan Gotthardt
No relevant relationships to disclose
Edward A. Fox
No relevant relationships to disclose
Sigitas Jonas Verselis
No relevant relationships to disclose
Ashok Kumar
Employment or Leadership Position - KARD Scientific
Sylvia A. Holden
Consultant or Advisory Role - Cellceutix
Siya Ram
Employment or Leadership Position - KARD Scientific
Stock Ownership - Cellceutix
Karima Chafai-Fadela
Employment or Leadership Position - KARD Scientific
Kimberly Harding
Employment or Leadership Position - KARD Scientific
Krishna E. Menon
Employment or Leadership Position - Cellceutix
Stock Ownership - Cellceutix